Vivoryon Therapeutics N.V. (LON:0R3M)
London · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 28.58M -13.0% |
| Revenue (ttm) | n/a |
| Net Income | -5.83M |
| EPS | -0.20 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 779 |
| Open | 1.180 |
| Previous Close | 1.130 |
| Day's Range | 1.105 - 1.180 |
| 52-Week Range | 1.020 - 1.820 |
| Beta | 1.45 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Vivoryon Therapeutics
Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon ... [Read more]
News
Vivoryon Therapeutics Earnings Call Transcript: Q2 2026
Advanced licensing and financing negotiations are underway for varoglutamstat, which continues to show strong clinical and preclinical results in diabetic kidney disease. Expenses and net loss decreased year-over-year, with a cash runway into Q4 2026 and blockbuster sales potential confirmed.
Vivoryon Therapeutics Quarterly report: Q2 2026
Vivoryon Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Vivoryon Therapeutics Earnings release: Q2 2026
Vivoryon Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Vivoryon Therapeutics Slides: Q2 2026
Vivoryon Therapeutics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Vivoryon Therapeutics Quarterly report: Q1 2026
Vivoryon Therapeutics has published its Q1 2026 quarterly earnings report on June 11, 2026.
Vivoryon Therapeutics Earnings Call Transcript: Q4 2025
Varoglutamstat showed robust efficacy in diabetic kidney disease, especially in high-risk patients, with strong preclinical and clinical data supporting its advancement to phase II-B. Financial discipline reduced losses, and a recent capital raise extends the cash runway into Q4 2026.
Vivoryon Therapeutics Annual report: Q4 2025
Vivoryon Therapeutics has published its Q4 2025 annual report on April 23, 2026.
Vivoryon Therapeutics Earnings release: Q4 2025
Vivoryon Therapeutics released its Q4 2025 earnings on April 23, 2026, summarizing the period's financial results.
Vivoryon Therapeutics Slides: Q4 2025
Vivoryon Therapeutics has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on April 23, 2026.
Vivoryon Therapeutics N.V. Reports Full Year 2025 Financial Results and Provides Business Update
Vivoryon Therapeutics N.V. Reports Full Year 2025 Financial Results and Provides Business Update Compelling kidney function data and meta-analysis from two Phase 2 studies with varoglutamstat presente...
Vivoryon Therapeutics Slides: Investor presentation
Vivoryon Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on March 11, 2026.
Vivoryon Therapeutics Earnings Call Transcript: Q3 2025
Phase II data for varoglutamstat showed significant kidney function improvement, including in severe cases, with a strong safety and efficacy profile. Reduced R&D spending and a successful private placement extended cash runway into Q3 2026.
Vivoryon Therapeutics Earnings release: Q3 2025
Vivoryon Therapeutics released its Q3 2025 earnings on December 4, 2025, summarizing the period's financial results.
Vivoryon Therapeutics Slides: Q3 2025
Vivoryon Therapeutics has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on December 4, 2025.
Vivoryon Therapeutics Earnings Call Transcript: Q2 2025
Lead candidate varglutemstat showed significant kidney function improvements in Phase II studies, with new preclinical data supporting expansion into rare diseases. Financials improved year-over-year, and preparations for a Phase 2b study are underway, pending additional funding.
Vivoryon Therapeutics Quarterly report: Q2 2025
Vivoryon Therapeutics has published its Q2 2025 quarterly earnings report on September 4, 2025.
Vivoryon Therapeutics Slides: Q2 2025
Vivoryon Therapeutics has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on September 4, 2025.